Sanofi And Regeneron To Increase Praluent Accessibility For High-Risk Patients

Study Cholesterol drug Praluent lowers risk of death heart attack

Inc. All rights reserved. This material may not be published broadcast rewritten or redistributed

Sanofi and Regeneron will be meeting with USA health plans to discuss potential net pricing adjustments for those that agree to provide straightforward access for high-risk patients.

Results from the trial were presented during a late-breaker session at the American College of Cardiology's (ACC) 67 Annual Scientific Session in Orlando on Saturday.

Praluent was shown to have cut down the overall risk of major adverse cardiovascular events (MACE) by 15%, which is the primary endpoint of the trial. Management sees population of 300K - 400K high-risk patients in USA, only 38K being treated at present.

In addition to significantly reducing the primary endpoint-a combined rate of heart attack, stroke, hospitalization for unstable angina or death from coronary heart disease-alirocumab was also associated with a 15 percent reduction in death from any cause among the full patient population and a 29 percent reduction in death from any cause among those who started the trial with LDL cholesterol above 100 mg/dL.

Blackhawks fade away in third period, drop 7-4 decision to Bruins
It's what they're going to see, and hopefully the referees, the officials - I just asked what the call was - interference. Quenneville coached his 1,608th game, moving him past Al Arbour for second most on the NHL's all-time list.

Praluent was also associated with a 15% reduction in all-cause mortality, and numerically fewer deaths from coronary heart disease.

Alirocumab inhibits the binding of proprotein convertase subtilisin/kexin type 9 (PCSK9) to the LDL receptor and thus heightens the number of available LDL receptors on the surface of liver cells.

In terms of safety and tolerability, the only significant difference between the two study groups was minor local site reactions (mild itching, redness or swelling) at the injection site, which occurred in 3.1 percent of those receiving alirocumab and 2.1 percent of those receiving placebo.

The intention is to take a precision medicine approach to addressing the burden of cardiovascular disease, by focusing efforts on high-risk patients most vulnerable for future CV events, such as those who have suffered a previous event and are unable to reduce their LDL cholesterol (LDL-C) below 100 mg/dL despite statin therapy.

McLaren BP23 Hyper-GT emerges as the company's fastest auto ever
Speaking at the 2018 Geneva Motor Show , CEO of McLaren Automotive, Mike Flewitt revealed more details about the latest hypercar. We should see it in all its glory later this year before production starts in 2019.

For those in the Praluent treatment arm, an estimated 75% of patient time was on the 75 mg dose.

"Many patients who have survived a recent heart attack or other coronary event are unable to reach an LDL cholesterol goal of less than 100 mg/dL, and have an urgent need for new therapeutic options due to their increased risk of another event".

ICER's latest analysis sets a value-based price range of $4,500-8,000 per year, net of rebates and discounts, for this group, and the companies have said they will offer discounts of up to 69% to health insurers that reduce prescribing obstacles and will be meeting with United States health plans to discuss pricing adjustments. "Through this trial, we have been able to identify high-risk patients treated with optimal statins who still have an urgent need for additional treatment options".

"We believe a new paradigm is needed in how all members of the healthcare community collaborate to ensure that patients are able to affordably access the medical treatments they need", said Regeneron chief executive Leonard Schleifer in a statement.

Man Utd youngster McTominay earns first Scotland call-up
Three more uncapped players are in the squad: Millwall goalkeeper Jordan Archer, Fulham midfielder Kevin McDonald and Rangers winger Jamie Murphy.

The ODYSSEY OUTCOMES data, backed with a public commitment to work with payers to reduce prices in patients who stand to benefit the most, is the flawless riposte to Amgen.

Latest News